Tower Research Capital (TRC)’s Citius Oncology CTOR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.98K	Buy	+13,816	New	+$11K	﹤0.01%	4045
2025 Q4	–	Sell	-11,846	Closed	-$24K	–	5709
2025 Q3	$24K	Buy	+11,846	New	+$25.7K	﹤0.01%	3138
2025 Q1	–	Sell	-41	Closed	-$47	–	5936
2024 Q4	$47	Hold	41	–	–	﹤0.01%	5549
2024 Q3	$57	Hold	41	–	–	﹤0.01%	5558
2024 Q2	$466	Hold	41	–	–	﹤0.01%	5321
2024 Q1	$453	Sell	41 -34	-45%	-$374	﹤0.01%	5484
2023 Q4	$820	Sell	75 -5	-6%	-$54	﹤0.01%	5491
2023 Q3	$862	Sell	80 -4	-5%	-$43	﹤0.01%	5455
2023 Q2	$885	Buy	+84	New	+$878	﹤0.01%	5524

Other funds holding CTOR

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s CTOR Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Citius Oncology (CTOR) in Q2 2026: 13,816 shares worth $8.98K. The stake represents ﹤0.01% of the portfolio and ranks #4045 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CTOR as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in CTOR in Q2 2023 and has held it in 9 quarters since. The position peaked at $24K in Q3 2025. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

Tower Research Capital (TRC) held 13,816 shares of Citius Oncology worth $8.98K as of Q2 2026.
Citius Oncology was a new Tower Research Capital (TRC) position in Q2 2026.
Citius Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4045 holding.
Tower Research Capital (TRC) first reported a position in Citius Oncology in Q2 2023 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s Citius Oncology position peaked at $24K in Q3 2025.
19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.